Board Member
Crinetics Pharmaceuticals, Inc.
Equibles does not estimate personal net worth.
Get an email with a short summary when Amylyx Pharmaceuticals, Inc. publishes a filing, an earnings call transcript or a press release.
Get AMLX alertsCamille Bedrosian is recorded as Board Member at Crinetics Pharmaceuticals, Inc.. The newest filing on record that lists Camille Bedrosian as Board Member at Crinetics Pharmaceuticals, Inc. is dated April 29, 2026. The proxy statement of Amylyx Pharmaceuticals, Inc. reports total compensation of $1,567,674 for Camille Bedrosian in fiscal 2025, including a base salary of $575,000. Disclosed compensation is on record for 7 fiscal years. Camille Bedrosian has spoken on 3 earnings calls across 1 company, most recently for Amylyx Pharmaceuticals, Inc. on November 5, 2026. Amylyx Pharmaceuticals, Inc. is classified in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. Crinetics Pharmaceuticals, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Amylyx Pharmaceuticals, Inc. includes Joshua Cohen (CEO and Board Member), Justin Klee (CEO and Board Member), James Frates (CFO) and 3 others.
“TBH is a chronic metabolic condition characterized by recurrent and often debilitating hypoglycemia that can lead to cognitive impairment, confusion, and in some cases, seizures or loss of consciousness.”
“TBH is characterized by recurrent and often debilitating hypoglycemia thought to be caused by an exaggerated GLP-1 response, primarily after food intake.”
“PBH is a chronic metabolic condition driven by an exaggerated GLP-1 response, primarily after food intake, resulting in persistent, recurrent, and often debilitating hypoglycemia.”
Proxy statement
Start not stated–present
Last confirmed April 23, 2026
Crinetics Pharmaceuticals, Inc.
Board Member
Proxy statement
Start not stated–present
Last confirmed April 29, 2026
Proxy statement
Start not stated–2023-04-24
Last confirmed by a filing; no departure on record
Drug Manufacturers - Specialty & Generic · Healthcare
Crinetics Pharmaceuticals, Inc.
Biotechnology · Healthcare
Board Member
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Amylyx Pharmaceuticals, Inc. (AMLX) | Chief Medical Officer | $575,000 | $1,567,674 |
| 2023 | Amylyx Pharmaceuticals, Inc. (AMLX) | Chief Medical Officer | $56,763 | $2,372,859 |
| 2022 | Ultragenyx Pharmaceutical Inc. (RARE) | Chief Medical Officer and Executive Vice President | $596,000 | $3,755,268 |
| 2021 | Ultragenyx Pharmaceutical Inc. (RARE) | Chief Medical Officer and Executive Vice President | $567,123 | $3,344,722 |
| 2020 | Ultragenyx Pharmaceutical Inc. (RARE) | Chief Medical Officer and Executive Vice President | $546,686 | $2,214,680 |
| 2019 | Ultragenyx Pharmaceutical Inc. (RARE) | Chief Medical Officer and Executive Vice President | $511,186 | $2,485,654 |
| 2018 | Ultragenyx Pharmaceutical Inc. (RARE) | M.D. Chief Medical Officer and Executive Vice President | $442,308 | $4,836,128 |
